Developed for:
Access Patients in Their Communities
Hawthorne Health is a community-based site network designed to support enrollment, retention, and execution.
Access changes everything.
Hawthorne Health is a pharmacy-based site network designed to support sponsors, like AstraZeneca, seeking to expand patient access through community-based clinical research across rheumatology, cardiology, endocrinology, gastroenterology, and dermatology studies.
Our model engages patients through trusted healthcare settings, including clinics, pharmacies, and affiliated community care locations across the United States. Centralized operational oversight and standardized workflows support protocol-compliant execution while helping reduce barriers to participation and retention.
Pharmacy-Based Site Network
Built to reach patients traditionally excluded from existing research models, Hawthorne Health brings clinical trials to the heart of communities through a nationwide network of pharmacy-based sites.
Familiar settings and convenient locations help to reduce barriers to participation while improving patient retention and study outcomes.
Proposed Network Overview
We have identified a set of community-based sites and investigators aligned to support your pipeline, selected based on:
Existing patient flow within relevant populations
Established care relationships in local communities
Geographic distribution to support enrollment coverage
Ability to support both site-based and lower-burden visit structures
Hawthorne Health Site Locations
Hawthorne Site Demographics
Nephrology
Renal Outcomes | 4 Sites
Sites selected for chronic kidney disease, diabetic kidney disease, and renal outcomes experience, including large Phase 3 and event-driven designs.
Nephrology and cardio-renal investigators for outcomes research:
-
PI Highlights:
Board-certified nephrologist with experience across approximately 27 or more kidney and dialysis-focused trials, including large Phase 3 studies in CKD, ESRD, and renal outcomes. Deep specialization spanning phosphate binders, anemia management, and diabetic nephropathy supports high-quality enrollment and execution in nephrology trials.
Catchment:
Densely populated, highly diverse area (~53% minority representation), access to approximately 22,500 patients.
-
PI Highlights:
Hands-on experience across multiple chronic kidney disease and proteinuric kidney disease studies, including interventional and observational research. Critical care and complex patient management background supports execution in the medically challenging populations common to renal trials.
Catchment:
Community-based site serving a diverse regional population, including approximately 29.5% Black or African American patients.
Cardio-Metabolic
Type 2 Diabetes | 5 Sites
Sites aligned to Phase 3 type 2 diabetes research, including diabetic kidney disease, cardiovascular outcomes, and weight-related metabolic endpoints. Texas sites are excluded from this program per sponsor criteria.
Investigators experienced across T2DM and cardiometabolic endpoints:
-
PI Highlights:
Directly relevant Type 2 diabetes experience, including major Phase 3 studies focused on diabetic nephropathy and cardiovascular outcomes. Long-standing nephrology leadership provides deep expertise managing T2DM patients with renal complications, with strong alignment to metabolic, cardiovascular, and kidney endpoints.
Catchment:
Densely populated, highly diverse area (~53% minority representation), access to approximately 22,500 patients.
-
PI Highlights:
Metabolic and endocrine research experience, including an SGLT-based licogliflozin trial (Novartis LIK066). A high-volume Phase 1 and bioequivalence background reflects strong protocol adherence and patient management across metabolic and endocrine studies.
Catchment:
Regional healthcare hub for southwest Missouri and northern Arkansas with higher-than-average rates of obesity and diabetes.
READ BIO
Operational Model
One operational partner across sites and homes.
Hawthorne’s operating model is designed to simplify study execution across community sites and in-home settings through centralized governance and standardized processes.
Capabilities include:
One CTA across participating community sites
Centralized feasibility and startup oversight
Standardized workflows and reporting
One project management structure across visit locations
Nationwide in-home support capabilities
2,000+ GCP-trained clinicians
Coverage across all 50 U.S. states
60,000+ completed at-home study visits
Community Trial Solutions
Connecting AstraZeneca to community-based care environments patients already utilize every day.
Benefits to Partnering with Hawthorne Health:
Eliminate patient barriers
Drive greater enrollment
Increase retention
Improve study compliance
Kayla Marinelli
Director, BD
Kayla brings a combination of clinical care and research business development experience, supporting sponsors and CROs across community-based clinical research environments. As part of the business development team at Hawthorne Health, she supports sponsor engagement and study opportunities focused on expanding patient access and improving operational execution.
Prior to Hawthorne, Kayla held business development roles at Profound Research and Atlantic Research Group, where she supported clinical trial growth across community-based site networks. Her background also includes direct patient care experience as a clinical nurse at UVA Health and Augusta Health Care for Women, providing a practical understanding of patient engagement and healthcare delivery within clinical settings.
